[
    [
        {
            "time": "2018-01-02",
            "original_text": "Eli Lilly Is Trading Strong Ahead of Earnings on Wednesday",
            "features": {
                "keywords": [
                    "Lilly",
                    "Trading Strong",
                    "Earnings"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly Is Trading Strong Ahead of Earnings on Wednesday",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy",
            "features": {
                "keywords": [
                    "Teva",
                    "Positive CHMP Opinion",
                    "Migraine Drug",
                    "Ajovy"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "5 of the Best Biotech Stocks to Buy Now",
            "features": {
                "keywords": [
                    "Best Biotech Stocks",
                    "Buy Now"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "5 of the Best Biotech Stocks to Buy Now",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis",
            "features": {
                "keywords": [
                    "Lilly",
                    "Phase 3 Results",
                    "Baricitinib",
                    "Atopic Dermatitis"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Lilly: Baricitinib Meets Primary Endpoint In BREEZE-AD1 And BREEZE-AD2",
            "features": {
                "keywords": [
                    "Lilly",
                    "Baricitinib",
                    "Primary Endpoint",
                    "BREEZE-AD1",
                    "BREEZE-AD2"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly: Baricitinib Meets Primary Endpoint In BREEZE-AD1 And BREEZE-AD2",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        }
    ]
]